These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19672628)

  • 21. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
    Finek J; Holubec L; Svoboda T; Sefrhansova L; Pavlikova I; Votavova M; Sediva M; Filip S; Kozevnikova R; Kormunda S
    Anticancer Res; 2009 Feb; 29(2):667-70. PubMed ID: 19331218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
    Pajk B; Cufer T; Canney P; Ellis P; Cameron D; Blot E; Vermorken J; Coleman R; Marreaud S; Bogaerts J; Basaran G; Piccart M
    Breast; 2008 Apr; 17(2):180-5. PubMed ID: 17976988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
    Morabito A; Filippelli G; Palmeri S; Cascinu S; Ferraù F; Zagonel V; Gattuso D; Catalano V; Capaccetti B; Franciosi V; Accurso V; Scinto F; Gasparini G
    Breast Cancer Res Treat; 2003 Mar; 78(1):29-36. PubMed ID: 12611454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study.
    Hassan M; Osman MM
    Hematol Oncol Stem Cell Ther; 2010; 3(4):185-90. PubMed ID: 21150238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
    Schmid P; Heilmann V; Schulz CO; Dieing A; Lehenbauer-Dehm S; Jehn C; Sezer O; Possinger K; Flath B
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):568-74. PubMed ID: 16044345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients.
    Ghosn M; Kattan J; Farhat F; Younes F; Gasmi J
    Anticancer Res; 2006; 26(3B):2451-6. PubMed ID: 16821631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
    Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
    Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
    Palomo AG; Glogowska I; Sommer H; Malamos N; Kilar E; Vega JM; Torrecillas L; Delozier T; Ettl J; Finek J
    Anticancer Res; 2012 Oct; 32(10):4539-45. PubMed ID: 23060583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
    Lorusso V; Crucitta E; Silvestris N; Guida M; Misino A; Latorre A; De Lena M
    Clin Breast Cancer; 2003 Jun; 4(2):138-41. PubMed ID: 12864942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
    Nolè F; Crivellari D; Mattioli R; Pinotti G; Foa P; Verri E; Fougeray R; Brandely M; Goldhirsch A
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
    Verma S; Wong NS; Trudeau M; Joy A; Mackey J; Dranitsaris G; Clemons M
    Am J Clin Oncol; 2007 Jun; 30(3):297-302. PubMed ID: 17551309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
    Gioulbasanis I; Saridaki Z; Kalykaki A; Vamvakas L; Kalbakis K; Ignatiadis M; Amarantidis K; Kakolyris S; Georgoulias V; Mavroudis D
    Anticancer Res; 2008; 28(5B):3019-25. PubMed ID: 19031950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
    Tan WW; Allred JB; Salim M; Flynn P; Fishkin PA; Stella PJ; Wiesenfeld M; Bernath AM; Fitch TR; Perez EA
    Clin Breast Cancer; 2012 Apr; 12(2):81-6. PubMed ID: 22444716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine and vinorelbine in metastatic breast cancer.
    Chan A; Verrill M
    Eur J Cancer; 2009 Sep; 45(13):2253-65. PubMed ID: 19464166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
    Hess D; Thürlimann B; Pagani O; Aebi S; Rauch D; Ballabeni P; Rufener B; Castiglione-Gertsch M; Goldhirsch A;
    Ann Oncol; 2004 Dec; 15(12):1760-5. PubMed ID: 15550580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.